In Vivo Evaluation of Indium-111-Labeled 800CW as a Necrosis-Avid Contrast Agent.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FKM, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D’Angiolella V, Dawson TM, Dawson VL, de Laurenzi V, de Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, di Daniele N, di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, el-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G (2018) Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ 25(3):486–541

Malhotra R, Lin Z, Vincenz C, Brosius FC (2001) Hypoxia induced apoptosis via two independent pathways in Jurkat cells: differential regulation by glucose. Am J Physiol Cell Physiol 281(5):C1596–C1603

Lee SY, Ju MK, Jeon HM et al (2018) Regulation of tumor progression by programmed necrosis. Oxid Med Cell Longev 2018:3537471. https://doi.org/10.1155/2018/3537471

Bredholt G, Mannelqvist M, Stefansson IM, Birkeland E, Bø TH, Øyan AM, Trovik J, Kalland KH, Jonassen I, Salvesen HB, Wik E, Akslen LA (2015) Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. Oncotarget 6(37):39676–39691

Richards CH, Mohammed Z, Qayyum T, Horgan PG, McMillan DC (2011) The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. Future Oncol 7(10):1223–1235

Silva MT (2010) Secondary necrosis: the natural outcome of the complete apoptotic program. FEBS Lett 584(22):4491–4499

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247

Abdulla S, Saada J, Johnson G, Jefferies S, Ajithkumar T (2015) Tumour progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma. Clin Radiol 70(11):1299–1312

Xie B, Stammes MA, van Driel PBAA, Cruz LJ, Knol-Blankevoort VT, Löwik MAM, Mezzanotte L, Que I, Chan A, van den Wijngaard JPHM, Siebes M, Gottschalk S, Razansky D, Ntziachristos V, Keereweer S, Horobin RW, Hoehn M, Kaijzel EL, van Beek ER, Snoeks TJA, Löwik CWGM (2015) Necrosis avid near infrared fluorescent cyanines for imaging cell death and their use to monitor therapeutic efficacy in mouse tumor models. Oncotarget 6(36):39036–39049

Xie B, Tomaszewski MR, Neves AA, Ros S, Hu DE, McGuire S, Mullins SR, Tice D, Sainson RCA, Bohndiek SE, Wilkinson RW, Brindle KM (2017) Optoacoustic detection of early therapy-induced tumor cell death using a targeted imaging agent. Clin Cancer Res 23(22):6893–6903

Stammes MA, Maeda A, Bu J et al (2016) The necrosis-avid small molecule HQ4-DTPA as a multimodal imaging agent for monitoring radiation therapy-induced tumor cell death. Front Oncol 6:221

Salah S, Lewin J, Amir E, Abdul Razak A (2018) Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: a systematic review and meta-analysis. Cancer Treat Rev 69:1–10

Cona M, Li J, Feng Y, Chen F, Verbruggen A, Witte P, Oyen R, Ni Y (2014) Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations. Anti Cancer Agents Med Chem 14(6):852–861

Abma E, Peremans K, De Vos F et al (2018) Biodistribution and tolerance of intravenous iodine-131-labelled hypericin in healthy dogs. Vet Comp Oncol 16(3):318–323

Jiang B, Wang J, Ni Y, Chen F (2013) Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imaging. Theranostics 3(9):667–676

Ji Y, Zhan Y, Jiang C, Jiang X, Gao M, Liu W, Li Y, Wang J, Wang Q, Cona MM, Yao N, Wang X, Fang Z, Yin Z, Zhang J, Sun Z, Ni Y (2014) Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis. J Drug Target 22(4):304–312

Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P (2002) St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54(4):349–356

Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pai LH, McMurry T, Gansow OA, Pastan I, Paik CH (1994) Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med 35(5):882–889

Zhao J, Chen J, Ma S, Liu Q, Huang L, Chen X, Lou K, Wang W (2018) Recent developments in multimodality fluorescence imaging probes. Acta Pharm Sin B 8(3):320–338

Hernandez R, Heskamp S, Rijpkema M, Bos DL, Goldenberg DM, McBride WJ, Morgenstern A, Bruchertseifer F, Cai W, Boerman OC (2017) Preventing radiobleaching of cyanine fluorophores enhances stability of nuclear/NIRF multimodality imaging agents. Theranostics 7(1):1–8

Stammes MA, Knol-Blankevoort VT, Cruz LJ, Feitsma HRIJ, Mezzanotte L, Cordfunke RA, Sinisi R, Dubikovskaya EA, Maeda A, DaCosta RS, Bierau K, Chan A, Kaijzel EL, Snoeks TJA, van Beek ER, Löwik CWGM (2016) Pre-clinical evaluation of a cyanine-based SPECT probe for multimodal tumor necrosis imaging. Mol Imaging Biol 18(16):905–915

Keller T, López-Picón FR, Krzyczmonik A, Forsback S, Takkinen JS, Rajander J, Teperi S, Dollé F, Rinne JO, Haaparanta-Solin M, Solin O (2019) Comparison of high and low molar activity TSPO tracer [(18)F]F-DPA in a mouse model of Alzheimer’s disease. J Cereb Blood Flow Metab 40:1012–1020. https://doi.org/10.1177/0271678x19853117

van Manen L, Handgraaf HJM, Diana M, Dijkstra J, Ishizawa T, Vahrmeijer AL, Mieog JSD (2018) A practical guide for the use of indocyanine green and methylene blue in fluorescence-guided abdominal surgery. J Surg Oncol 118(2):283–300

Marshall MV, Draney D, Sevick-Muraca EM, Olive DM (2010) Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats. Mol Imaging Biol 12(6):583–594

Rosenthal EL, Warram JM, De Boer E et al (2015) Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer. Clin Cancer Res 21(16):3658–3666

Price EW, Orvig C (2014) Matching chelators to radiometal for radiopharmaceuticals. Chem Soc Rev 43(1):260–290